AURA Biopharm AS was founded in 2016 by a team of scientists and drug developers with many years experience in academia and major pharmaceutical companies and a proven track record of success in drug development.
We focus on development of novel and breakthrough therapies for unmet medical needs mainly in four areas of interest where a scientific, medical and business opportunity arises.
AUR-1001 is a first in class pathogenic-tailored drug for the prevention of thrombosis and fetal loss in patients with anti-phospholipid syndrome. There is an unmet medical need for new treatment in this condition.
